Defining Recurrent Disease With Axumin™

NCT ID: NCT03996993

Last Updated: 2019-06-25

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 20 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-07-01
• Study Completion Date: 2020-12-30

Brief Summary

This project seeks to use advanced imaging (specifically, positron emission tomography/computed tomography [PET/CT]) to detect, locate, and characterize recurrent disease in the setting of patients with prostate cancer.

Detailed Description

This protocol details the study design for patients with prostate cancer (PCa) who have failed primary treatment with radical prostatectomy, and now have rising PSA as indicated by a recent PSA blood draw value > 0.1 ng/ml. Patients fitting our inclusion criteria for the study, will receive an Axumin scan as part of their standard of care (SOC) treatment. If the SOC scan is positive, patients under this protocol will either subsequently receive hormone therapy OR salvage radiation therapy (not both concurrently). Patient response to therapy will be assessed with serial Axumin scans identifying additional lesions present at 3 months, 6 months, and 12 months (1 year) post-therapy, with the latter time point being our endpoint of the study.

The study aims are as follows:

1. The investigators would like to understand the hormonal therapy response based on Axumin scans administered over a time course of 3 months, 6 months, and 12 months post-hormone therapy treatment.

2. The investigators would like to understand the salvage radiotherapy response based on Axumin scan results incorporated into radiation treatment planning over a time course of 3 months, 6 months, and 12 months post-salvage radiation treatment.

Conditions

Prostate Cancer; Prostate Adenocarcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Hormone Therapy Cohort

Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA \> 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.

Casodex, Axumin

Intervention Type: DRUG

Patients will receive hormone therapy if Axumin positive area appears.

Salvage Radiotherapy Cohort

Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA \> 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.

Salvage Radiation, Axumin

Intervention Type: RADIATION

Patients will receive salvage radiation therapy if Axumin positive area appears.

Interventions

Casodex, Axumin

Patients will receive hormone therapy if Axumin positive area appears.

Intervention Type: DRUG

Salvage Radiation, Axumin

Patients will receive salvage radiation therapy if Axumin positive area appears.

Intervention Type: RADIATION

Other Intervention Names

Lupron

Eligibility Criteria

Inclusion Criteria

General requirements:

1. Karnofsky performance status of >50 (or ECOG/WHO equivalent).

2. Age > 18.

3. Ability to understand a written informed consent document, and the willingness to sign it.

4. History of histologically confirmed adenocarcinoma of the prostate and underwent radical prostatectomy for primary treatment with curative intent.

5. Men diagnosed with recurrent/persistent prostate cancer disease following radical prostatectomy based on a detectable or rising PSA value ≥ 0.1 ng/ml.

6. Positive commercial standard of care (SOC) Axumin scan at time of restaging disease.

7. Patients should not have been previously treated for biochemical recurrence (BCR) (i.e., this is the first diagnosis for BCR.

8. Language proficiency in English, Spanish, Japanese, Korean, Vietnamese. Our office has translators to coherently translate the consent documents to patients.

1. Ability to tolerate androgen deprivation therapy (Casodex and Lupron) indefinitely.

2. Been off ADT for minimum of 3 months.

3. Ability to receive a possible of 4 Axumin PET/CT scans within a year.

1. Considering salvage radiotherapy.

2. Ability to tolerate salvage radiation therapy for 8 weeks.

Exclusion Criteria

General requirements:

1. Patients not capable of getting PET study due to weight, claustrophobia, allergic reaction, and/or inability to lay still for the duration of the exam.

2. Women and children.

3. Men currently on or seeking primary treatment (surgery or radiation) for prostate cancer.

4. History of bilateral orchidectomy.

5. Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy. This includes focal ablation techniques (HiFu).

6. Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist).

7. Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.

1. Being considered for salvage radiotherapy.

2. Androgen deprivation therapy (ADT) in the past 3 months.

1. Currently on ADT or on ADT within the past 3 months.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Cancer Center of Irvine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Kenneth Tokita

Irvine, California, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Kenneth M Tokita, MD

Role: primary

kmtokita@ccoi.org

949-417-1100

Other Identifiers

2018/12/7

Identifier Type: -

Identifier Source: org_study_id